Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 23:11:100113.
doi: 10.1016/j.obpill.2024.100113. eCollection 2024 Sep.

Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024

Suzanne Cuda  1 , Marisa Censani  2 , Valerie O'Hara  3 , Jennifer Paisley  4 , Roohi Kharofa  5 , Rushika Conroy  6 , Brooke Sweeney  7 , Cristina Fernandez  8 , Meredith L Dreyer Gillette  9 , Nancy T Browne  10
Affiliations

Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024

Suzanne Cuda et al. Obes Pillars. .

Abstract

Background: This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) details assessment and management of the child with overweight or obesity. The term "child" is defined as the child between 2 and 12 years of age. Because children are in a continual state of development during this age range, we will specify when our discussion applies to subsets within this age range. For the purposes of this CPS, we will use the following definitions: overweight in the child is a body mass index (BMI) ≥ 85th and <95th percentile, obesity in the child is a BMI ≥95th percentile, and severe obesity is a BMI ≥120% of the 95th percentile.

Methods: The information and clinical guidance in this OMA Clinical Practice Statement are based on scientific evidence, supported by medical literature, and derived from the clinical perspectives of the authors.

Results: This OMA Clinical Practice Statement provides an overview of prevalence of disease in this population, reviews precocious puberty in the child with obesity, discusses the current and evolving landscape of the use of anti-obesity medications in children in this age range, discusses the child with obesity and special health care needs, and reviews hypothalamic obesity in the child.

Conclusions: This OMA Clinical Practice Statement on the child with obesity is an evidence based review of the literature and an overview of current recommendations. This CPS is intended to provide a roadmap to the improvement of the health of children with obesity, especially those with metabolic, physiological, psychological complications and/or special healthcare needs. This CPS addresses treatment recommendations and is designed to help the clinician with clinical decision making.

Keywords: Anti-obesity medications; Autonomic dysregulation; Child; HO/ROHHAD; Hypothalamic dysfunction; Hypoventilation; Obesity; Precocious puberty; Rapid-onset obesity; Special health care needs.

PubMed Disclaimer

Conflict of interest statement

Authors of this Clinical Practice Statement received no payment for their writing, editing, and publishing work. While listed journal Editors received payment for their roles as Editors, they did not receive payment for their participation as authors.Suzanne Cuda: Rhythm Gold panel, Rhythm Advisory Board. Marisa Censani: none. Valerie O'Hara: Novo Nordisk speaker: telehealth conference 2023. Jennifer Paisley: Rhythm Pharmaceuticals speakers bureau. Roohi Kharofa: Rhythm Pharmaceuticals: EMANATE trial. Rushika Conroy: GOLD academy faculty for Rhythm Pharmaceuticals. Brooke Sweeney: Rhythm Pharmaceutical: Speaker, Consultant, BEAM Project, and Research support; no financial support; Consulting Novo Nordisk, past consultant Nestle Corp. and Eli Lilly. Cristina Fernandez: Rhythm Pharmaceutical: Council HPS and BEAM Project, No financial compensation. Meredith Dryer: none. Nancy T. Browne: none.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Summary of key points about the child with precocious puberty and obesity.
Fig. 2
Fig. 2
The multidisciplinary team for the child with SHCN and obesity. (Original Figure).
Fig. 3
Fig. 3
Summary of the care of the child with SHCN and obesity. (Original Figure).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Stierman B., Afful J., Carroll M., et al. National health and nutrition examination survey 2017–march 2020. 2021. Natl Health Stat Rep. 2020 https://stacks.cdc.gov/view/cdc/106273
    1. Hu K., Staiano A.E. Trends in obesity prevalence among children and adolescents aged 2 to 19 years in the US from 2011 to 2020. JAMA Pediatr. 2022;176(10):1037–1039. doi: 10.1001/jamapediatrics.2022.2052. - DOI - PMC - PubMed
    1. Mirza N., Phan T.L., Tester J., Fals A., Fernandez C., Datto G., Estrada E., Eneli I. A narrative review of medical and genetic risk factors among children age 5 and younger with severe obesity. Child Obes. 2018 Oct;14(7):443–452. doi: 10.1089/chi.2017.0350. - DOI - PMC - PubMed
    1. Shashaj B., Bedogni G., Graziani M.P., et al. Origin of cardiovascular risk in overweight preschool children: a cohort study of cardiometabolic risk factors at the onset of obesity. JAMA Pediatr. 2014;168(10):917–924. doi: 10.1001/jamapediatrics.2014.900. - DOI - PubMed
    1. Baughcum A.E., Gramling K., Eneli I. Severely obese preschoolers in a tertiary care obesity program: characteristics and management. Clin Pediatr. 2015;54(4):346–352. doi: 10.1177/0009922814555975. - DOI - PubMed

LinkOut - more resources